- WORLD EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
VBL Therapeutics Launches First Israeli Site as Part of the GLOBE International Pivotal Trial for VB-111
VBL Therapeutics (NASDAQ:VBLT) announced enrollment of the first patient in Israel, as part of the GLOBE Phase 3 pivotal trial for lead candidate VB-111.
VBL Therapeutics (NASDAQ:VBLT) announced enrollment of the first patient in Israel, as part of the GLOBE Phase 3 pivotal trial for lead candidate VB-111.
According to the company:
The trial, which was commenced in the US in August 2015, is comparing VB-111 in combination with bevacizumab (AvastinĀ®) to bevacizumab alone in recurrent glioblastoma (rGBM). GLOBE has been designed to recruit approximately 252 patients in the US, Canada and Israel, and is expected to include 6 leading Israeli medical centers.
Tzahala Tzuk-Shina, MD, Head of the Neuro-oncology Unit, Rambam Health Care Campus, Haifa, Israel commented:
The huge unmet need for an effective therapy in glioblastoma warrants clinical evaluation of novel therapies.Ā We are proud to be the first Israeli clinical site in this important rGBM trial and will continue our efforts to provide patients with access to innovative clinical options such as VB-111.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to theĀ cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.Ā